AACR announces recipients of Outstanding Investigator Award for Breast Cancer Research
October 02, 2015
Supported by Bristol-Myers Squibb, this AACR lectureship has been established to recognize outstanding science that has inspired or has the potential to inspire new perspectives on the etiology, diagnosis, treatment or prevention of breast cancer. The lectureship is selected by the San Antonio Breast Cancer Symposium Program Committee.
Ashworth is recognized for his contribution to the discovery of the BRCA2 gene and his team's identification of the synthetic lethality between BRCA mutations and PARP inhibitors. The high sensitivity of BRCA1 or BRCA2 mutant cells to PARP inhibitors forms the rationale behind clinical trials that are now assessing the potential of these agents.
Ashworth will deliver his lecture entitled, "Synthetic Lethal Approaches to Cancer Therapy" on Friday, Dec. 10, 2010, from 11:30 a.m. - 12:00 p.m. CT.
The CTRC-AACR San Antonio Breast Cancer Symposium is a four-day program that presents a balance of clinical, translational and basic research. It provides a forum for interaction, communication and education for a broad spectrum of researchers, health care professionals and those with a special interest in breast cancer.
Source: University Medical Center